Loading…
Traded Mar 16, 2026 · Filed Mar 18, 2026
Dexcom's Chief Legal Officer sold $110K of Dexcom shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$110,245
Shares × reported transaction price
32 days after results of Feb 12, 2026, 45 days before results of Apr 30, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $66.34 on Mar 16, 2026, 21% above its 52-week low and 26% below its high, after a 9% drop over the previous 30 trading days
52-week range $54.84 (Nov 10, 2025) to $89.53 (Jul 28, 2025), 33% of the way up, from 251 adjusted closes. 30 trading days earlier: $73.04 on Jan 30, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Oct 27, 2025 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.
4 such cases were open. Prime v. DexCom, Inc., docket 1:25-cv-08912, via CourtListener (court records). Nature of suit 850, company named as first defendant
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -1.8% | -2.2% | +0.5% |
| 30 days | -3.9% | +7.4% | -11.3% |
| 90 days | +5.9% | +12.3% | -6.4% |
| 180 days | +28.5% | +14.8% | +13.7% |
Past results only. Not a forecast.
Compensation award — excluded from discretionary-purchase analysis.
Routine share withholding; mechanical by default.